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SUMMARY
Background—The relationships between primary sclerosing cholangitis (PSC) and the 
environment are largely unknown.
Aims—To validate associations reported in previous studies and to identify novel environmental 
exposures among PSC patients.
Methods—We performed a multicenter, case–control analysis utilising self-administered 
questionnaires. Responses between cases (n = 1000) and controls (n = 663) were compared using 
multivariable logistic regression adjusted for age and gender. The model was further stratified 
based on inflammatory bowel disease (IBD) status (with IBD n = 741 without IBD n = 259).
Results—Smoking was associated with PSC only when IBD was present (OR, 0.5; 95% CI 0.4–
0.7) but not among those PSC patients without IBD (OR, 0.9; 95% CI 0.7–1.2). Compared to 
controls, women with PSC (irrespective of the presence of IBD) were less likely to have received 
hormone replacement therapy (HRT; OR, 0.5; 95% CI 0.4–0.7) and were more likely to have 
recurrent urinary tract infections (OR, 1.6; 95% CI 1.2–2.3). PSC patients regardless of gender or 
IBD status were less likely to eat fish (OR, 0.4; 95% CI 0.3–0.6) and grilled/barbecued meat (OR, 
0.8; 95% CI 0.7–0.9). In contrast, PSC patients with and without IBD were more likely to 
consume steak/burgers that were more well done (OR, 1.3; 95% CI 1.2–1.5).
Conclusions—IBD (rather than PSC) is associated with smoking. Women with PSC are more 
likely to have recurrent urinary tract infections and less likely to receive HRT. Dietary intake and 
methods of food preparation differ in PSC patients when compared to controls.
INTRODUCTION
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterised by 
inflammation of the intra and or extrahepatic bile ducts.1, 2 Population based cohorts from 
Europe and North America report that 68–73% of PSC patients have concurrent 
inflammatory bowel disease (IBD), typically ulcerative colitis (UC).3, 4 Although the 
pathogenesis of PSC remains ill-defined, it may develop through immune-mediated 
mechanisms triggered by complex gene-environment interactions in susceptible 
individuals.1
There is a growing body of evidence, which suggests environmental exposures may play a 
role in the pathogenesis of immune-mediated conditions. For example, an increased 
incidence of IBD has been observed in industrialised nations and migrants who leave 
‘developing’ areas and become established in industrialised regions.5–8 Dietary factors such 
as fast food intake, sweets, fats and animal protein have been associated with IBD, which 
adds credence to the hypothesis that environmental risk factors and a western lifestyle may 
contribute to the pathogenesis of IBD.6 In turn, dietary practices can affect the composition 
of the human microbiome and metabolome and it has been postulated that alterations in the 
intestinal microbiome may play a key role in the pathogenesis in IBD and PSC.9–11
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Despite advances in our knowledge of exposures associated with other immune-mediated 
conditions, our understanding of non-genetic risk factors associated with PSC and 
concurrent IBD (PSC-IBD) and PSC without IBD (PSC-woIBD) is limited. Four studies 
have reported a negative association with smoking and PSC.12–15 However, a negative 
association between smoking and UC without PSC has also been reported16 and it is 
possible that the presence of IBD among PSC patients may act as a confounder when 
examining disease-environment associations related to PSC (rather than IBD). 
Tonsillectomy and hormone-based contraceptives were also reported to have a negative 
association with PSC.14, 15 While appendectomy has been reported to be less common 
among patients with UC, an association between having an appendectomy and PSC was not 
observed in a previous report.14 Although two studies independently suggested a negative 
association with coffee and PSC, data concerning other dietary habits is unknown.15, 17
A comprehensive assessment of environmental factors associated with PSC is important. 
Identification of such exposures would enhance our understanding of the disease 
pathogenesis, lay the foundation for future studies to delineate important gene-environment 
interactions between select genes and environmental exposures, contribute to future 
therapies and guide preventative measures in at risk populations. However, many of the 
reports that have examined exposures associated with PSC have been limited to a small 
subset of environmental factors, localised to a single centre or had a small sample size, 
which makes adjusting for the presence of IBD challenging. Therefore, we performed a 
large, prospective multicenter study with two key aims: (i) identify novel exposures 
associated with PSC among those with and without IBD; (ii) validate or refute 
environmental exposures that could potentially be associated with PSC (regardless of IBD 
status) that have been described in previous studies.
METHODS
Subjects
Patients with PSC were prospectively identified and recruited to participate in the present 
study from 2004 to 2013. The PSC patients were seen and recruited from a consortium of 
eight academic medical centres in the USA and Canada, which comprise a large study 
group, entitled: PSC Resource of Genetic Risk, Environment and Synergy Studies 
(PROGRESS). In addition, a subset of PSC patients were self-referred (i.e. not seen as a 
patient and recruited through one of the eight centres) and contacted the lead study centre to 
participate in the study (Figure S1). Patients were diagnosed with PSC by standard methods 
and the diagnosis was confirmed by review of the medical record.18 However, 33 self-
referred patients had a self-reported history of PSC but did not have medical records 
available to confirm the diagnosis. These patients were included in the primary analysis and 
later excluded in a sensitivity analysis (below).
Control patients were recruited from the Mayo Clinic Division of General Internal Medicine 
during visits for preventative health care. Like the cases, the controls resided from areas 
across North America (71% of controls and 90% of cases lived outside of Minnesota). 
Controls with a history of liver disease were excluded. This study was approved by the 
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institutional review board for each participating centre and conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki.
Data collection and study instrument
Cases and controls were directly given or mailed (in a prepaid envelope) a paper 
questionnaire at the time of enrolment. If a patient did not return the questionnaire after 2 
months a second form was mailed. The 37-page survey consisted of 70 primary questions 
and 300 secondary questions and was developed by the Mayo Clinic Survey Center. The 
survey collected detailed, self-reported information concerning patient demographics, 
education, medical/surgical history and environmental exposures including dietary habits. 
The dietary questions concerning food frequency were based on a subset of the previously 
validated Block 1995 Revision of the Health Habits and History Questionnaire.19–21 Female 
patients were asked about their obstetric and gynecological history, history of urinary tract 
infections (UTIs), use of hormone replacement therapy (HRT) and hormone-based 
contraceptives. A self-diagnosis and reporting of UTIs has previously been shown to be 
reliable and accurate.22 We reviewed the electronic medical histories of a subset of female 
patients (n = 166) who had regular primary care visits at the lead study site to determine the 
accuracy of self-reported HRT use and history of recurrent UTIs in our questionnaire as 
compared to the medical record. Indeed, there was near perfect agreement between the 
survey answers for HRT use (99%) and recurrent UTIs (98%) and the medical record. In 
addition, a questionnaire-based assessment of IBD status among PSC patients has been 
examined and has been shown to have a near perfect agreement with patient medical records 
in a previous study.15 Moreover, several of the items included in the questionnaire form 
were similar to those in other questionnaire-based studies among patients with cholestatic 
liver disease published previously.14, 15, 23 Subjects were asked about their exposure history 
at the time of the questionnaire and not asked to recall if an exposure occurred before being 
diagnosed with PSC with the exception of smoking.
Statistical analysis
For the unadjusted results, categorical data are reported as percentages and compared using 
the χ2 test. Continuous data are reported as medians and interquartile ranges and compared 
using the Wilcoxon rank sum test. Patients with missing data were not included in the 
analysis for that particular missing covariate. Because of age and gender differences 
between the groups, logistic regression analysis was used to compare cases and controls 
adjusting for age and gender. In addition to displaying results using odds ratios (OR) and 
95% confidence intervals (CI), descriptive statistics for the control data were adjusted to 
have the same age and gender distribution of the cases. Consequently, the number of 
subjects is not reported.
Patient responses that differed significantly between cases and controls or those exposures 
examined in prior studies underwent a secondary analysis where the IBD patients in the 
control group were excluded and PSC patients were stratified into two subgroups (self-
reported history of PSC-IBD and PSC-woIBD) and compared to controls using a generalised 
logistic model adjusting for age and gender. This was done to mitigate the potential 
confounding effect of IBD when assessing the role of environmental factors associated with 
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PSC. Finally, the consistency of the results from the stratified analysis was assessed by five 
sensitivity analyses which excluded the following patients: age less than 21 years (n = 67), 
self-reported diagnosis of PSC (n = 33), history of a liver transplant (n = 230), a subset of 
patients where the IBD status could not be verified due to a lack of medical records 
available for the lead study centre to corroborate the diagnosis of IBD (n = 147) and patients 
with Crohn’s disease or indeterminate colitis (confirmed by chart review) or their IBD status 
could not be verified (n = 486; i.e. included only those cases with confirmed UC). Variables 
that achieved statistical significance in the models for both PSC subgroups and remained 
significant in the sensitivity analyses were considered to be associated with PSC. All tests 
were 2-sided and a P < 0.05 was considered significant. The analysis was performed using 
SAS 9.3 (SAS Institute; Cary, NC, USA) and R 3.0.2 (R Foundation for Statistical Computing, 
Vienna, Austria).
RESULTS
Subjects included & demographical features
One-thousand six hundred and sixty-three subjects were included. The response rate was 
74% (1000/1354) for cases and 86% (663/774) for controls. Cases who responded were 
more likely to be older (55.6 years vs. 50.8 years, P < 0.001), Caucasian (95% vs. 90%, P = 
0.04) and have been seen at the primary study site (69% vs. 63%, P = 0.04). The sites of 
enrolment for the cases are shown in Figure S1. PSC patients were younger, had a lower 
body mass index (BMI), and were less likely to be Caucasian and female when compared to 
controls (Table 1).
Comorbidities in subjects
After adjusting for age and gender, controls were more likely to report their health as 
‘excellent,’ ‘very good’ or ‘good’ when compared to PSC patients (91% vs. 71%, P < 
0.001). IBD was reported among nine controls (UC n = 4; Crohn’s disease n = 4; 
indeterminate colitis n = 1) and 741 cases (UC n = 538; Crohn’s disease n = 110; 
indeterminate colitis n = 93). Among the 853 (85%) patients where their IBD status could be 
verified based on medical record review, 795 (93%) had records which were consistent with 
the patients IBD status reported on the questionnaire. In addition, we were able to verify 
through the medical record that 230 patients with PSC and UC were diagnosed with either 
condition at least 5 years apart. A diagnosis of UC occurred at least 5 years after the 
diagnosis of PSC in 28 (12%) patients while a diagnosis of PSC occurred at least 5 years 
after the diagnosis of UC in 202 (88%) individuals. There were no differences among their 
demographical features, smoking history or other exposure history between the PSC first 
and UC first groups (data not shown). Compared to controls, coeliac disease was more 
common among PSC patients (1% vs. 2%, P = 0.01). However, the prevalence of other 
immune-mediated conditions was similar between cases and controls (Table S1).
The medical and surgical history of cases stratified by the self-reported IBD status is shown 
in Table 2. Those with PSC-IBD were more likely to be diagnosed with PSC at a younger 
age (35.0 years vs. 45.0 years, P < 0.001) and have a longer duration of PSC (7.4 years vs. 
5.6 years, P < 0.01) but were less likely to have a self-reported diagnosis of autoimmune 
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hepatitis (5% vs. 8%, p<0.03) when compared to those with PSC-woIBD. Colon cancer was 
more common among those with PSC-IBD vs. PSC-woIBD (8% vs. 1%, Table 2). However, 
the prevalence of colon cancer among PSC-woIBD was the same for controls (P = 0.70). 
The severity of liver disease based on a self-reported history of hepatic malignancy or a 
prior liver transplant was similar between the two PSC groups (Table 2).
Assessment of exposures and events examined in prior studies: smoking, tonsillectomy, 
appendectomy, hormone-based contraception
The proportion of current smokers was similar between cases and controls (Table 3). In 
addition, exposure to second hand smoke or chewing tobacco was similar between PSC 
patients and controls (Table S1). In contrast, 37% of controls reported a smoking history 
(>100 cigarettes during a lifetime) compared to 25% of patients with PSC (P < 0.001) 
(Table 3). The median age of smoking onset was 18 years for both patients and controls. 
However, controls had a greater personal smoking exposure (pack-years): 10.5 (4.5–21.8) 
vs. 5.6 (2.3–15.0), P = 0.05 (Table 3). Following stratification, the negative association 
between smoking history and PSC was observed only among those with PSC-IBD patients 
and not in the PSC-woIBD group (Table 4). Similarly, those with PSC-IBD had fewer pack-
years before PSC was diagnosed when compared to the total pack-year exposure among 
controls (PSC-IBD: OR, 0.9; 95% CI 0.7–0.9). However, the duration of smoking before a 
diagnosis of PSC did not differ between PSC-woIBD patients and the total pack-year 
exposure for controls (PSC-woIBD: OR, 0.9; 95% CI 0.8–1.1).
Tonsillectomy was not associated with PSC (Tables 3 and 4). In contrast, controls were 
more likely to have undergone an appendectomy when compared to cases (Table 3). 
However, in the stratified analysis, appendectomy was associated with PSC-IBD but not 
PSC-woIBD when compared to controls (PSC-IBD: OR, 1.8; 95% CI 1.3–2.3; PSC-woIBD: 
OR, 1.1; 95% CI 0.8–1.6; Table 4).
Among the women enrolled in the study, the proportion of PSC patients and controls who 
reported a history (current or previous) of hormone-based contraception use was similar 
(Table 3) and there was no association with hormone-based contraception and PSC in the 
stratified analysis (Table 4). Akin to a prior study, our questionnaire did not distinguish 
between the various types of hormone-based contraceptives.15
The above observations concerning smoking, tonsillectomy, appendectomy and hormone-
based contraceptives remained consistent in the sensitivity analyses and none of these 
variables were associated with both PSC subgroups, even after excluding patients with 
Crohn’s disease and indeterminate colitis from the PSC-IBD subgroup (Tables S2–S6).
Novel exposures among women
Compared to female controls, women with PSC were more likely to report recurrent UTIs 
(Table 3) and this positive association persisted regardless of the presence of IBD (PSC-
IBD: OR, 1.5; 95% CI 1.01–2.2; PSC-woIBD: OR, 2.0; 95% CI 1.2–3.2) (Table 4). 
However, there was no association observed between the frequency of recurrent UTIs and 
PSC (Table 3).
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Women with PSC were less likely to have received HRT when compared to female controls 
(Table 3) and this negative association continued after stratifying cases based on the 
presence of IBD (PSC-IBD: OR, 0.6; 95% CI 0.4–0.8; PSC-woIBD: OR, 0.5; 95% CI 0.3–
0.8) (Table 4). In contrast, we did not detect a relationship between duration of HRT use and 
PSC (Table 3).
In the sensitivity analyses, both recurrent UTIs and HRT therapy continued to be associated 
with PSC, regardless of IBD status (Tables S2–S6).
Dietary habits and methods of food preparation
Several dietary habits and methods of food preparation were found to have an association 
with PSC prior to stratification (Figure 1). However, after PSC patients were stratified based 
on their IBD status the frequency of the following food intake had either a positive or 
negative association among those with IBD but not PSC-woIBD: steak/burger (fast food or 
pan fried), chicken (grilled), fast food or pan-fried food (chicken-steak-burgers), fish and 
fruit (Figures 2 and 3).
In contrast, several types of food and methods of preparation were more common in controls 
compared to both PSC-IBD and PSC-woIBD groups (Figures 2 and 3). Indeed, there was a 
negative association with PSC and consumption of grilled steak or burgers and a composite 
variable which included grilled or barbecued meat (PSC-IBD: OR, 0.8; 95% CI 0.7–0.9; 
PSC-woIBD: OR, 0.9; 95% CI 0.7–0.98; Figure 2). Similarly, PSC patients were less likely 
to eat fish (yes vs. no) than controls (PSC-IBD: OR, 0.4; 95% CI 0.2–0.6; PSC-woIBD: OR, 
0.5; 95% CI 0.3–0.8). However, our ability to detect a difference in the frequency of fish 
intake among those without IBD may have been limited by our smaller sample size in that 
subgroup (Figure 3). Vegetables appeared to be consumed less frequently in PSC patients 
when compared to controls (PSC-IBD: OR, 0.9; 95% CI 0.8–0.9; PSC-woIBD: OR, 0.9; 
95% CI 0.9–0.997). However, statistical significance of this observation did not persist in 
the PSC-woIBD subgroup when we excluded patients whose IBD status could not be 
verified (PSC-IBD: OR, 0.9; 95% CI 0.8–0.9; PSC-woIBD: OR, 0.9; 95% CI 0.9–1.01; 
Table S5).
In addition to potential protective dietary associations, certain methods of food preparation 
had a positive association with PSC following stratification (Figure 2). For example, 
cooking steak or burgers so they are more well done was associated with PSC (PSC-IBD: 
OR, 1.4; 95% CI 1.2–1.5; PSC-woIBD: OR, 1.3; 95% CI 1.1–1.4) despite a negative 
association with grilled steak or burgers. While the point estimates and confidence intervals 
suggest that the frequency of fast food and pan-fried food consumption may also be 
associated with PSC, this did not reach statistical significance which could be secondary to 
our limited power to detect differences in each subgroup (Figure 2).
The negative association between PSC and grilled and barbecued meat, and fish intake 
persisted in the sensitivity analyses (Tables S2–S6). Similarly, the positive association 
between cooking red meat so it is more well done also remained consistent in the sensitivity 
analyses (Tables S2–S6).
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DISCUSSION
To date, this study represents the largest cohort of PSC patients assembled to examine novel 
and previously explored environmental exposures and events associated with PSC. The size 
of the cohort, which represents about 3.4% of the predicted number of PSC patients in the 
USA,4 enabled us to examine the relationships of exposures among PSC patients with and 
without IBD when compared to controls. This strategy is important because IBD is a 
common comorbid condition among PSC patients and may act as confounder, when trying 
to elucidate potential risk factors associated with PSC rather than IBD.
In contrast to prior studies, our findings suggest that the relationship between smoking and 
PSC may be driven by the presence of IBD.16 Indeed, a prior history of smoking and the 
total duration of smoking were lower among those cases with IBD when compared to 
controls, but this was not observed among PSC-woIBD patients. This observation persisted 
when we excluded those with Crohn’s disease or indeterminate colitis (Table S6). The 
largest prior study (also a questionnaire-based study), which examined smoking and PSC 
included a total of 240 cases (57 without IBD) and found that a history of smoking was more 
prevalent in controls when compared to cases (43% vs. 20%) and the proportion of PSC 
patients with a history of smoking was similar among those with and without IBD (PSC-
IBD n = 19% vs. PSC-woIBD n = 22%).15 Our current study also found a similar difference 
between controls and all PSC patients (37% vs. 25%). However, despite having nearly five 
times as many PSC patients without IBD, we were unable to detect an association with PSC 
and smoking when IBD was absent. Similarly, we were unable to validate an association 
between PSC and either a tonsillectomy or hormone-based contraceptive use, which has 
been previously described.14, 15 Lastly, our results reaffirmed a prior observation that an 
appendectomy is not associated with PSC.14
We detected two exposures associated with PSC among women. Our results suggest women 
with PSC are less likely to receive HRT. Indeed, PSC is more common in men and this 
observation raises the question if increased oestrogen could play a role in the gender 
differences observed among PSC patients.1 Oestrogen has been shown to have anti-
inflammatory properties via the down regulation of chemoattractant proteins and vascular 
cell adhesion molecules.24, 25 Furthermore, HRT has been shown to have a protective effect 
on IBD disease activity in a dose-dependent manner.26 In contrast to the negative 
association between PSC and HRT, women with PSC were more likely to have recurrent 
UTIs when compared to controls. UTIs have been associated with other immune-mediated 
liver diseases such as primary biliary cirrhosis.27 This is postulated to occur through 
molecular mimicry between antigens in the microorganism and endogenous host proteins.27 
Future studies should examine the relationship between oestrogen and recurrent UTIs and 
PSC.
Apart from coffee intake, the role of diet and PSC has been largely unexplored.15, 17 In this 
study, PSC patients were less likely to consume fish. We also observed a negative 
association between grilled or barbecued meat (chicken, steak or burger) and a positive 
association with how well done steak or burgers were cooked and PSC. Yet, the frequency 
of chicken, steak or burger consumption was not associated with PSC unless the method of 
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food preparation was taken into account. Furthermore, there appeared to be a relationship 
between an increased frequency of fast food or pan-fried food intake and decrease frequency 
of vegetable consumption and PSC (Figure 2), but this did not reach statistical significance 
in both subgroups in all of the subsequent analyses (Tables S2–S6).
Differences in dietary habits may be relevant to the pathogenesis of PSC. A variety of 
immune-mediated conditions including IBD have been associated the so-called ‘western 
diet’ which is enriched in fats, sugars and processed foods and low in vegetables.28 Dietary 
choices can impact the microbiome, metabolome, cellular barriers and the immune 
system.29–31 It is plausible that such changes could create favourable conditions for the 
development of PSC in susceptible individuals. Indeed, the microbiome, disruption of 
cellular barriers and upregulation of the immune system have been postulated to play a role 
in the pathogenesis of PSC.1, 10 Patients with PSC were less likely to consume fish. Similar 
to our findings, a diet high in fish has been associated with a decreased risk of immune-
mediated conditions such as rheumatoid arthritis.32, 33 High concentrations of n−3 fatty 
acids can be found in some fish.34 Low intake of n−3 fatty acids has been associated with an 
upregulation of a variety of immune functions.35 In contrast, n−3 fatty acids have anti-
inflammatory properties through a variety of mechanisms.36 Docosahexaenoic acid, an n−3 
fatty acid, appears to attenuate cholestatic liver injury in animal models following bile duct 
ligation.37 Furthermore, docosahexaenoic acid has been shown to decrease serum alkaline 
phosphatase levels in patients with PSC and a reduction in serum alkaline phosphatase level 
has been linked with improved outcomes.38, 39 However, n−3 fatty acid concentrations can 
vary between fish species and cooking techniques.34 Therefore, the relationship between 
fish and PSC may be more complex and other factors (fish type, origin, cooking method and 
host influences) may also contribute to this association. In addition to fish consumption, our 
findings suggest the methods of food preparation may be important in PSC. Such variations 
in the cooking processes can impact the microbiome differently.40 In addition, cooking 
steaks or burgers so they are more well done was associated with PSC and this cooking 
practice has been shown to increase the presence of dietary advanced glycoxidation end 
products (AGEs).41, 42 Receptors for AGE (RAGE) can be found in a variety of locations, 
but they appear to be strongly expressed in cholangiocytes when compared to other cell 
populations in the liver.43 Stimulation of RAGE can lead to production of proinflammatory 
cytokines, vascular adhesion molecules and increase vascular permeability.44 In animal 
models, a diet high in AGE can lead to hepatic inflammation without steatosis.45 
Furthermore, AGE has also been shown to stimulate RAGE gene expression, exacerbate 
oxidative stress and increase hepatic fibrosis.46 While these potential pathogenic 
mechanisms are largely speculative, future studies are needed to examine the complex 
relationships between the diet, microbiome, metabolome, immune system and the host 
genome among PSC patients.
Our study has several limitations. First, our survey may be subject to recall bias and we are 
unable to assess the timing of each exposure relative to the onset of PSC. To overcome this 
limitation, cases would need to be captured prospectively before the diagnosis or at the time 
of the PSC diagnosis. However, this would be very challenging since PSC is a rare disease 
with a subclinical disease course. Second, our study design does not enable us to 
demonstrate causality and we cannot conclude that altering ones exposure of one or more of 
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the associations presented herein could either prevent PSC or alter the disease course. Third, 
we were unable to recruit a sufficient number of young and middle-aged men as controls. 
This prevented us from directly matching cases and controls based on their age and gender. 
To mitigate this imbalance, we performed logistic regression analysis adjusting for age and 
gender when comparing exposures between cases and controls.
In conclusion, our results have expanded the pool of potential risk and protective factors 
which may be associated with PSC. Our data demonstrate that smoking is only associated 
with PSC when IBD is present, which suggest this observation is secondary to IBD rather 
than PSC. Among women with PSC, HRT use is less common whereas recurrent UTIs occur 
more frequently when compared to controls. In addition, fish, grilled or barbecue meat 
consumption was more common in controls. In contrast, PSC patients were more likely to 
consume red meat that was more well done. These findings have the potential to lay the 
foundations for future studies, which seek to examine the complex interplay between genes 
and environmental exposures in PSC.
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Figure 1. 
Dietary habits and methods of food preparation in cases compared to controls (unstratified). 
CI, confidence interval; Freq, frequency; C-S-B, chicken-steak-burger.
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Figure 2. 
Dietary habits and methods of food preparation in cases stratified based on inflammatory 
bowel disease status compared to controls (Part 1). CI, confidence interval; Freq, frequency; 
C-S-B, chicken-steak-burger; PSC-IBD, primary sclerosing cholangitis with inflammatory 
bowel disease; PSC-woIBD, primary sclerosing cholangitis without inflammatory bowel 
disease.
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Figure 3. 
Dietary habits and methods of food preparation in cases stratified based on inflammatory 
bowel disease status compared to controls (Part 2). CI, confidence interval; Freq, frequency; 
PSC-IBD, primary sclerosing cholangitis with inflammatory bowel disease; PSC-woIBD, 
primary sclerosing cholangitis without inflammatory bowel disease.
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Table 2
Medical and surgical history among cases by IBD status
PSC-IBD (n = 741) PSC-woIBD (n = 259) P-value*
Age at PSC diagnosis (years) 35.0 (25.0–45.0) 45.0 (35.0–55.0) <0.001
PSC duration (years) 7.4 (2.8–13.4) 5.6 (1.7–11.1) <0.01
Liver transplantation 24% 21% 0.35
Hepatic malignancy† 5% 5% 0.69
Autoimmune hepatitis 5% 8% 0.03
IBD type
 Crohn’s disease 15% – –
 Ulcerative colitis 73% –
 Indeterminate colitis 13% –
IBD age diagnosis (years) 25.0 (15.0–45.0) – –
IBD duration (years) 12.9 (5.9–26.6) – –
Colon cancer 8% 1% <0.001
Colectomy 31% 1% <0.001
PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease.
*Age- and sex-adjusted P-values.
†
Hepatic malignancy includes self-reported history of cholangiocarcinoma or ‘liver cancer’ (cholangiocarcinoma n = 21; ‘liver cancer’ n = 36).
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Table 3
Exposures (nondietary) and events reported by cases and controls*
Controls (n = 663) Cases (PSC) (n = 1000) P-value
Exposures and events examined previously
 Smoking (ever)† 37% 25% <0.001
 Currently smoke cigarettes 8% 7% 0.38
 Pack-years (total) 10.5 (4.5–21.8) 5.6 (2.3–15.0) 0.05
 Appendectomy 18% 25% <0.001
 Tonsillectomy (ever) 35% 30% 0.23
 Tonsillectomy ≤19 years 30% 28% 0.90
 Hormone-based contraception use (ever)‡ 84% 74% 0.15
 Age started hormone-based contraception (years)‡ 20.0 (18.0–22.0) 20.0 (18.0–23.0) 0.89
Novel exposures‡
 HRT Use (ever) 40% 28% <0.001
Age started HRT (years) 47.0 (43.0–48.0) 48.0 (42.0–50.0) 0.42
Number of years using HRT
 <1 year 18% 16% 0.47
 1–5 years 36% 32%
 6–10 years 21% 26%
 ≥11 years 25% 26%
Recurrent UTIs 20% 27% <0.01
Frequency of UTIs
 Once every 2 years 43% 34% 0.69
 Once every years 21% 25%
 ≥2 times per years 36% 40%
PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease; HRT, hormone replacement therapy; UTIs, urinary tract infections.
*Control values are age- and gender-adjusted to the distribution of the cases. Therefore, the number of subjects is not reported. The P-value is 
derived from the logistic regression model adjusting for age and gender.
†
Ever smoking defined as a history of smoking >100 cigarettes over lifetime.
‡Among women only (controls n = 488; cases n = 381).
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Table 4
Selected nondietary exposures and events stratified based on IBD status*
OR (95% CI), P-value
PSC vs. controls PSC-IBD vs. controls PSC-woIBD vs. controls
Cigarettes smoking
 Ever smoked >100 cigarettes 0.6 (0.5–0.8), <0.001 0.5 (0.4–0.7), <0.001 0.9 (0.7–1.2), 0.52
 Pack-years (total, per 10 years) 0.9 (0.8–1.1), 0.053 0.8 (0.7–0.95), 0.012 1.0 (0.8–1.1), 0.64
Surgical history
 Appendectomy 1.6 (1.2–2.0), 0.001 1.8 (1.3–2.3), <0.001 1.1 (0.8–1.6), 0.52
 Tonsillectomy 0.9 (0.7–1.1), 0.23 0.8 (0.6–1.1), 0.13 1.0 (0.7–1.3), 0.86
 Tonsillectomy ≤19 years 1.0 (0.8–1.3), 0.91 0.9 (0.7–1.2), 0.67 1.1 (0.8–1.5), 0.57
Female specific covariates
 Hormone-based contraception use (ever) 0.8 (0.5–1.1), 0.15 0.7 (0.5–1.1), 0.09 0.90 (0.5–1.5), 0.65
 HRT use (ever) 0.5 (0.4–0.7), <0.001 0.6 (0.4–0.8), <0.01 0.5 (0.3–0.8), <0.01
 Recurrent UTIs 1.6 (1.2–2.3), <0.01 1.5 (1.01–2.2), 0.047 2.0 (1.2–3.2), <0.01
IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; PSC-IBD, PSC with IBD; PSC-woIBD, PSC without IBD; OR, odds ratio; 
CI, confidence interval; HRT, hormone replacement therapy; UTIs, urinary tract infections.
*Adjusted for age and gender. Controls with inflammatory bowel disease were excluded in the stratified analysis.
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